CTIS2023-508748-23-00招募中1 期
A Phase 1/2a Randomized, Double-Blind Placebo-controlled Study of Intra-articular Allocetra in Knee Osteoarthritis - ENX-CL-05-001
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Age 45 – 80 years, Chronic osteoarthritis of index knee with knee-related joint pain: At the screening visit, patient reports that their typical osteoarthritis knee pain when not using medication is = 4 out of 10., Radiographic evidence of knee osteoarthritis of Kellgren-Lawrence (K-L) Grade 2 or 3 in the index knee, assessed by X-ray., At least 4 measurements of daily pain in the index knee on a NRS of at least 5 out of 10, and no single score of more than 9, assessed over a period of 7 days during the screening period and following washout of at least 48 hours. If the patient is receiving a long-acting analgesic the washout will be extended to 5- half-lives of the analgesic medication(s). Acetaminophen and/or metamizole (dipyrone) may be used for pain during the weekly assessment., Patients with knee pain who have failed to respond adequately to at least 3 months of conventional therapy., Willing to abstain from other intra-articular treatments and adhere to the protocol restrictions for concomitant medications and therapies during the study., Women of childbearing potential and all men must agree to use 2 methods of an adequate contraception: One barrier method (e.g., diaphragm, or condom or sponge, each of which are to be combined with a spermicide) and one hormonal method (e.g., oral, transdermal patch, implanted contraceptives or intrauterine device) prior to study entry and for the duration of study participation through 4 weeks following IP administration. Subjects that are highly unlikely to conceive (e.g., surgically sterile, postmenopausal, or not heterosexually active) are exempt., Ability of the patient to understand, and willingness to provide informed consent as described in this study protocol, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol., At the discretion of the Investigator, ability to comply with all study procedures, availability for the duration of the study, and ability and willingness to return for follow-up visits.
排除标准
- •Wheelchair bound., BMI >40., Any malignancy requiring active treatment within the last 3 years prior to screening (with the exception of non-melanoma skin cancer and in-situ breast cancer)., Any major surgical cartilage treatment (such as, but not limited to, ACI, OATS) in the index knee within 12 months prior to screening, or any minor surgical cartilage treatment (such as, but not limited to, microfracture) within 6 months prior to screening., Any ligamentous repair or malalignment correction in the index knee within 6 months prior to screening visit., Major injury to the index knee, such as torn ligament or severe sprain within 6 months prior to screening visit., Clinically relevant knee instability of the index knee on physical examination. Patients with clinically well-compensated instability such as well compensated ACL instability can be included., Large size synovial fluid effusion of the index knee at the screening visit., Valgus or varus alignment of the index knee >10 degrees or knee flexion contracture > 10 degrees., Dermatologic lesions on index knee that may interfere with injection site., Severe hip osteoarthritis ipsilateral to the index knee., Any live vaccine administered less than 30 days prior to the screening visit., Clinically significant widespread pain syndromes, as assessed by the Investigator, e.g., fibromyalgia, long COVID syndrome., Known hypersensitivity to any component of the study treatment or its excipients., Receipt of an IP or participation in other interventional clinical trials within 60 days prior to screening visit, unless approved by the Sponsor., Known coagulopathy, or use of anticoagulation medication or antiaggregant medication; however, up to 150 mg ASA daily is allowed., Previous intra-articular injection of steroid, hyaluronate, or other agent, into the index knee within 3 months prior to screening visit., Any of the following laboratory values at screening: hemoglobin <8.5 gm/dL, WBC <3500 per mm3 or >15,000 per mm3, platelet count <100,000/uL, creatinine >2 mg/dL, bilirubin >2 mg/dL, aspartate aminotransferase or alanine aminotransferase >3-fold higher than the ULN or international normalized ratio >1.2., Known severe cardiac or respiratory diseases including uncompensated congestive heart failure, ventricular arrhythmias, acute coronary disease, myocardial infarction within 6 months prior to screening visit, unstable angina, uncontrolled hypertension, severe pulmonary disease, or uncontrolled asthma., Known HIV infection (acute or chronic), uncured hepatitis C or hepatitis B infection., Any known psychiatric condition that, in the opinion of the Investigator, would make the patient unsuitable for the study (e.g., severe depression, suicidal ideation, or known drug or alcohol abuse within 1 year prior to screening visit)., Female patient is pregnant or breastfeeding, or planning to become pregnant or initiate breastfeeding while enrolled in the study., Immunosuppressive therapy, including oral (but not inhaled or topical) corticosteroids, less than 90 days prior to the screening visit. Oral corticosteroid treatment for diseases other than the disease under study, up to 5 mg per day is allowed (e.g., asthma)., Any known current or prior tumor of the index knee., Any known history or current intra-articular or osseous infection of the index knee., Pain in the contralateral knee of NRS 5 or more., Any evidence of clinically significant active infection anywhere in the body within a week prior
研究者
相似试验
Unknown
2 期
A Phase IIa Randomized, Double-Blind, Placebo Controlled Studyto Evaluate the Effects of Odanacatib (MK-0822) on Bone MineralDensity (BMD) and Overall Safety in the Treatment of Osteoporosisin Postmenopausal Women Previously Treated withAlendronateCTRI/2009/091/000218Merck Co Inc247
进行中（未招募）
1 期
A Randomized, Double-Blind and Placebo Controlled Study to Evaluate Efficacy and Safety of AMG 714 in Adult Patients with Refractory Celiac Disease not responding to gluten free diet and having the risk of intestinal T-cell lymphoma.Type II Refractory Celiac Disease (RCD-II)EUCTR2015-004063-36-FICelimmune LLC24
进行中（未招募）
1 期
Randomized, double-blind and placebo controlled medicinal trial, where efficacy and safety of AMG714 study drug is evaluated in adult patients with celiac disease.Celiac diseaseEUCTR2015-003647-19-FICelimmune LLC
进行中（未招募）
1 期
12 to 24 weeks of AZD4831 versus placebo for treatment of moderate to severe chronic obstructive pulmonary diseaseEUCTR2022-002441-18-ESAstraZeneca AB288
进行中（未招募）
1 期
An Efficacy and Safety Study of AZD4831 (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPDEUCTR2022-002441-18-DKAstraZeneca AB406